Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Tel Aviv
Pelles Sharon
23 years of experience
Clinic is certified :
Rectal cancer treatment cost in Israel typically runs between $22,500 and $35,000 for advanced surgical interventions. A standard diagnostic workup, including transrectal ultrasound, ranges from $200 to $500. Total expenses depend on the cancer stage, the use of robotic technology, and the hospital's status. Patients often see 20-40% savings compared to the US. Top treatment centers are located in Tel Aviv, Jerusalem, and Haifa.
Typical Rectal Cancer Treatment Costs in Israel
Bookimed Expert Insight: Patients seeking high-precision surgery should prioritize centers with robotic capabilities. Sourasky Medical Center (Ichilov) reports a 90% oncology success rate and utilizes AI-driven technologies. For complex cases involving peritoneal spread, the HIPEC expertise at Ichilov provides multidisciplinary value. Private options like Assuta Medical Center offer maximum patient control over surgeon selection. Jerusalem’s Hadassah Medical Center remains a premier choice for specialized gastrointestinal radiation therapy.
| Israel | Turkey | Austria | |
| Rectal resection | from $24,500 | from $10,250 | from $21,000 |
| NanoKnife | from $18,500 | from $9,500 | from $25,000 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | from $61,200 | from $22,500 | from $40,000 |
| Gastric polyps removal | from $2,200 | from $990 | from $5,000 |
| Da Vinci Robotic System | from $22,500 | from $9,500 | from $22,000 |
Dr. Sharon Peles leads the digestive tract tumors institute at Sourasky Medical Center, specializing in systemic treatments for rectal cancer.
Professor Merimsky leads the bone and soft tissue tumor department at Sourasky Medical Center, specializing in tailored oncology treatments.
Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.
She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.
Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Israeli oncology centers achieve 80–90% sphincter preservation for mid and high rectal tumors. Modern surgical techniques like low anterior resection (LAR) often avoid a permanent colostomy bag. The necessity depends on tumor location, response to preoperative therapy, and whether the anal sphincter remains functional.
Bookimed Expert Insight: Data shows that choosing high-volume centers like Sourasky Medical Center, which performs 34,000+ annual operations, significantly increases the chance of sphincter-saving surgery. Experienced surgeons like Dr. Hagit Tulchinsky specialize in restorative proctectomy. This reconstruction technique is a key factor in avoiding a permanent bag even for low-seated tumors.
Patient Consensus: Patients note that strong tumor shrinkage after initial radiation often changes the surgical plan from a permanent bag to a temporary one. Many emphasize that a successful 12-week recovery usually leads to a straightforward reversal procedure.
Israel provides advanced rectal cancer surgeries focused on sphincter preservation and precision. Leading centers like Sourasky and Sheba utilize the da Vinci robotic system for complex resections. Available techniques include Transanal Total Mesorectal Excision (TaTME) and HIPEC for treating advanced or metastatic cases.
Bookimed Expert Insight: Israeli oncology centers demonstrate high capability for complex cases, evidenced by the 14-night hospital stays included in Sourasky’s HIPEC packages. This extended monitoring period exceeds standard surgical recovery times, reflecting a focus on managing high-intensity treatments like cytoreductive surgery. This long-term inpatient care is a key differentiator for international patients seeking safety in major oncological procedures.
Patient Consensus: Patients emphasize the value of robotic-assisted options for preserving natural function and avoiding a permanent colostomy. Many note that getting a remote second opinion from Israeli specialists helps clarify if organ-preserving techniques like TEM are viable for their specific stage.
Advanced rectal cancer treatment in Israel focuses on molecular profiling and aggressive regional therapies. Patients access innovative options like MSI-H/dMMR immunotherapy, BRAF-targeted triplet regimens, and HIPEC. Specialist centers utilize robotic systems and CyberKnife for precise tumor destruction in metastatic cases.
Bookimed Expert Insight: Israeli oncology centers like Sourasky or Sheba often combine high-volume surgical expertise with molecular research. For instance, Dr. Joseph Klauzner has over 45 years of experience in complex colorectal cases. This experience is vital because successful metastatic treatment often requires a custom sequence of SIRT, HIPEC, and biological drugs.
Patient Consensus: Patients emphasize the necessity of biomarker testing for KRAS and BRAF before starting any systemic treatment. Many note that seeking a second opinion from high-volume hepatic surgeons is crucial if the cancer has spread to the liver.
Top treatment centers for rectal cancer in Israel are located in Tel Aviv, Ramat Gan, and Jerusalem. These JCI-accredited facilities include Sheba Medical Center and Sourasky Medical Center. Both rank among the top 10 hospitals globally according to Newsweek. They offer advanced robotic surgery and personalized oncology protocols.
Bookimed Expert Insight: While many choose Tel Aviv for its concentration of top-ranked clinics, Sheba Medical Center in Ramat Gan offers a unique City of Health model. It operates 6 specialized hospitals on one campus. This allows rectal cancer patients to access CAR-T therapy, TIL immunotherapies, and complex robotic resections in a single integrated location, which is rare even among the world's most elite medical institutions.
Patient Consensus: Patients note the efficiency of the international departments in Israel. They often mention that diagnostic results, which can take weeks elsewhere, are frequently completed in 3 to 5 days.